文献速递甲状腺疾病性腺与生殖内分泌

Graves病孕妇持续抗甲状腺药物治疗至分娩的新生儿甲状腺功能减退症发生率及危险因素

Incidence of and Risk Factors for Neonatal Hypothyroidism Among Women with Graves' Disease Treated with Antithyroid Drugs Until Delivery.
PubMed 文献 · Thyroid · 2023-02-21

回顾性队列纳入305例持续抗甲状腺药物至分娩的Graves病孕妇(甲巯咪唑63例、丙硫氧嘧啶242例),分娩时新生儿甲减发生率甲巯咪唑组19.0%(12/63)、丙硫氧嘧啶组12.8%(31/242);孕晚期日剂量是最强预测因素,甲巯咪唑切点10 mg/日、丙硫氧嘧啶切点150 mg/日。

要点

  • 持续抗甲状腺药物至分娩者新生儿甲减发生率甲巯咪唑组19.0%、丙硫氧嘧啶组12.8%。
  • 孕晚期日剂量是新生儿甲减最强预测因素,甲巯咪唑切点10 mg/日、丙硫氧嘧啶切点150 mg/日。
  • 孕晚期TRAb高于正常上限3倍时,甲巯咪唑切点20 mg/日、丙硫氧嘧啶切点150 mg/日。

核心结论

  • 新生儿甲减组母亲游离甲状腺素和TRAb水平更高,提示Graves病活动持续。
  • 当母亲Graves病仍活动且控制甲状腺毒症的抗甲状腺药物剂量无法减少时,需仔细随访。

研究设计与样本

  • 回顾性队列研究,纳入305例持续抗甲状腺药物至分娩的Graves病孕妇,其中甲巯咪唑组63例、丙硫氧嘧啶组242例。
  • 分娩时检测脐带促甲状腺激素、游离甲状腺素和TRAb水平,分析新生儿甲减与母亲游离甲状腺素、TRAb及孕期抗甲状腺药物日剂量的关系。
  • 新生儿甲减定义为脐带游离甲状腺素低于参考范围下限。

主要发现

  • 丙硫氧嘧啶组1例新生儿观察到甲状腺肿,2例婴儿需要左甲状腺素治疗。
  • 孕晚期抗甲状腺药物日剂量是分娩时新生儿甲减的最强预测因素,甲巯咪唑切点剂量为10 mg/日,丙硫氧嘧啶切点剂量为150 mg/日。
  • 孕晚期母亲TRAb水平高于正常范围上限3倍时,甲巯咪唑切点剂量为20 mg/日,丙硫氧嘧啶切点剂量为150 mg/日。

关键数值与推荐

  • 新生儿甲减诊断标准:脐带游离甲状腺素水平低于参考范围下限。
  • 孕晚期甲巯咪唑日剂量切点10 mg/日、丙硫氧嘧啶日剂量切点150 mg/日用于预测新生儿甲减风险。
  • 孕晚期TRAb高于正常上限3倍时,甲巯咪唑日剂量切点20 mg/日、丙硫氧嘧啶日剂量切点150 mg/日。

临床怎么用

  • 对持续抗甲状腺药物治疗至分娩的Graves病孕妇,尤其在母亲Graves病仍活动、抗甲状腺药物剂量无法减少时,应仔细随访新生儿甲状腺功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The incidence of neonatal hypothyroidism among newborns born to mothers with Graves' disease (GD) who continued antithyroid drug (ATD) treatment until delivery has never been reported. Objective: Our primary objective was to investigate the incidence of neonatal hypothyroidism among newborns born to mothers with GD who were treated with ATD until delivery. Our secondary objective was to identify the cutoff ATD daily doses for neonatal hypothyroidism risk, based on maternal thyrotropin (TSH) receptor antibody (TRAb) levels. Methods: We conducted a retrospective cohort study. We included 305 pregnant women with GD who were treated with an ATD until delivery (63 treated with methimazole [MMI] and 242 treated with propylthiouracil [PTU]). Umbilical cord TSH, free thyroxine (fT4), and TRAb levels were measured at delivery, and we investigated the respective relationships between neonatal hypothyroidism at delivery and maternal fT4 levels, TRAb levels, and daily ATD doses during pregnancy. Neonatal hypothyroidism was diagnosed when the umbilical cord fT4 level was below the lower limit of the reference range. Results: The incidence of neonatal hypothyroidism at delivery was 19.0% ([confidence interval, CI, 11.2-30.4]; 12/63) in the MMI group and 12.8% ([CI, 9.2-17.6]; 31/242) in the PTU group. Neonatal goiter was observed in one neonate in the PTU group, and two infants in the PTU group required levothyroxine treatment. The daily ATD dose in the third trimester was the strongest predictor of neonatal hypothyroidism at delivery; the cutoff MMI dose was 10 mg/day, and the cutoff PTU dose was 150 mg/day. When the maternal TRAb level in the third trimester was above three times the upper limit of the normal range, the cutoff MMI dose was 20 mg/day, and the cutoff PTU dose was 150 mg/day. Conclusions: Maternal fT4 and TRAb levels were higher in the neonatal hypothyroid group, which suggested prolonged GD activity. Careful follow-up is necessary when maternal GD remains active and the ATD dose to control maternal thyrotoxicosis cannot be reduced.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Yoshihara A, Noh JY, Inoue K, et al. Incidence of and Risk Factors for Neonatal Hypothyroidism Among Women with Graves' Disease Treated with Antithyroid Drugs Until Delivery. Thyroid. 2023. PMID: 36680759. doi:10.1089/thy.2022.0514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。